U.S., Jan. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07343934) titled 'huCART19-IL18-eDHFR Cells in Relapsed/Refractory Follicular Lymphoma' on Dec. 19, 2025.
Brief Summary: This is a phase 1, open-label study to evaluate the feasibility, safety and preliminary efficacy of huCART19-IL18-eDHFR cells administered in patients with relapsed or refractory follicular lymphoma. This study will be initiated as a single arm study (Treatment Arm A), which will evaluate the use of huCART19-IL18-eDHFR cells without prior lymphodepletion. In this Treatment Arm A, all subjects will receive a single flat dose of 7x10[6] huCART19-IL18-eDHFR cells (Dose Level 1; DL1). Additional treatment arms may also be introduced in...